B+
Bull case
20%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
MDAI
Spectral AICNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.45
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-05
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+62.5
Score
AI commentary
Primary filing evidence is strong, but forward visibility remains limited because the company is still transitioning from government-funded development to commercial revenue. Recent coverage is sparse and mixed, with no usable analyst revision set or social context; missing reaction data is not positive evidence. The deterministic prior is negative, so this remains a cautious monitoring view rather than an aggressive re-rating thesis [#SEC-8K-2026-08-12].
RankAlpha Sentiment Codex - 2026-09-05
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventUKCA label expansion and international launch readinessHigh impact
The company commenced label expansion through a U.K.-based study and targets UKCA authorization for sales in the U.K., Australia, or Gulf Cooperation Council countries by year-end 2026 [#SEC-8K-2026-08-12].
2026-12-31catalystFirst U.S. commercial sales by year-end 2026High impact
FDA De Novo clearance authorizes U.S. commercial distribution, and management targets first-ever commercial sales by year-end 2026. Execution, procurement timing, and initial demand remain unproven [#SEC-8K-2026-08-12].
2027-09-05catalystCommercial proof from the triage and treatment outcome studyHigh impact
Spectral plans to initiate a Q4 2026 U.S. study testing whether DeepView improves surgical precision, accelerates treatment decisions, and reduces length of stay. Positive evidence could support adoption, but timing and outcomes are uncertain [#SEC-8K-2026-08-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-05 • Updated nightlySource: Internal modelMethodology